Skip to Main Content

Author Details

Patricia Jaaks
Wellcome Sanger Institute
2015
17
12
PMIDPaper TitleJournal TitlePublished Year
35197630Effective drug combinations in breast, colon and pancreatic cancer cells.Nature2022
36241868AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.Oncogene2022
33273059AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib.Mol Cancer Ther2021
33339894SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.Br J Cancer2021
32487991Stratification and prediction of drug synergy based on target functional similarity.NPJ Syst Biol Appl2020
32073727Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies.Mol Syst Biol2020
33438807Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies.Mol Syst Biol2020
32627965Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens.Mol Syst Biol2020
32988967AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.Clin Cancer Res2020
30700749USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth.Sci Rep2019
29229604Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer.Cancer Res2018
28369813The proprotein convertase furin in tumour progression.Int J Cancer2017
28447920Prolonged circulation and increased tumor accumulation of liposomal vincristine in a mouse model of rhabdomyosarcoma.Nanomedicine (Lond)2017
26189795Targeting hedgehog signaling reduces self-renewal in embryonal rhabdomyosarcoma.Oncogene2016
27572312The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells.Oncotarget2016
27548722The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion.PLoS One2016
25620569The catalytic domain of inositol-1,4,5-trisphosphate 3-kinase-a contributes to ITPKA-induced modulation of F-actin.Cytoskeleton (Hoboken)2015
  • 1 - 17 of 17

Recommended Authors

Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 0
Noah E Berlow
Children's Cancer Therapy Development Institute
Career Start Year 2011
Number of shared co-authors 1
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Sander R van Hooff
Princess Maxima Center for Pediatric Oncology
Career Start Year 2008
Number of shared co-authors 0
Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 0
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 2
Jonathan Chou
University of California san francisco
Career Start Year 2005
Number of shared co-authors 0
Joseph A Ludwig
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 1
Joshua C Anderson
University of Alabama at Birmingham
Career Start Year 2005
Number of shared co-authors 0
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 0
Jalna Meens
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 0
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 1
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 1
Ken Kikuchi
Kyoto Prefectural University of Medicine
Career Start Year 2002
Number of shared co-authors 1
Trever G Bivona
University of California san francisco
Career Start Year 2002
Number of shared co-authors 2
Christopher D Willey
University of Alabama at Birmingham
Career Start Year 2000
Number of shared co-authors 1
Eric A Collisson
University of California san francisco
Career Start Year 1999
Number of shared co-authors 0
Annette T Byrne
Royal College of Surgeons in Ireland (RCSI)
Career Start Year 1999
Number of shared co-authors 3
Hai Hu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 0
William M Gallagher
All-Island Cancer Research Institute, UCD Conway Institute, University College Dublin
Career Start Year 1996
Number of shared co-authors 4
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 1
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 3
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 8
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 1
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 2
Enzo Medico
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Career Start Year 1988
Number of shared co-authors 4
Choh Yeung
Center for Cancer Research, National Cancer Institute
Career Start Year 1987
Number of shared co-authors 0
Charles Keller
Children's Cancer Therapy Development Institute
Career Start Year 1980
Number of shared co-authors 3
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 0

Collaborators

Mathew J Garnett
Wellcome Sanger Institute
Co-authored papers 10
Elizabeth A Coker
Wellcome Sanger Institute
Co-authored papers 6
Beat W Sch??fer
Department of Oncology and Children's Research Center, University Children's Hospital
Co-authored papers 4
Stephen Fawell
Oncology R&D
Co-authored papers 3
Julio Saez-Rodriguez
Institute of Computational Biomedicine, Heidelberg University
Co-authored papers 3
Ewa Koscielniak
Co-authored papers 2
Francis D Gibbons
Preclinical and Translational Sciences, Inc.
Co-authored papers 2
Barry R Davies
Oncology R&D
Co-authored papers 2
Cyril H Benes
Co-authored papers 2
Gareth P Gregory
School of Clinical Sciences at Monash Health, Monash University
Co-authored papers 1
Michael Zinda
Repare Therapeutics Inc.
Co-authored papers 1
William McCoull
Oncology R&D
Co-authored papers 1
Andrew R Leach
European Bioinformatics Institute (EMBL-EBI)
Co-authored papers 1
Robert B Diebold
Oncology R&D
Co-authored papers 1
Kate F Byth
Oncology R&D
Co-authored papers 1
Justin Cidado
Oncology R&D
Co-authored papers 1
Terry MacIntyre
Oncology R&D
Co-authored papers 1
Paula Lewis
Oncology R&D
Co-authored papers 1
Deborah Lawson
Oncology R&D
Co-authored papers 1
Nancy Su
Co-authored papers 1
Alwin G Schuller
Oncology R&D
Co-authored papers 1
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 1
Nuno A Fonseca
European Bioinformatics Institute
Co-authored papers 1
Martin Wild
Oncology R&D
Co-authored papers 1
Livio Trusolino
Candiolo Cancer Institute - FPO IRCCS
Co-authored papers 1
Angela Matchan
Wellcome Sanger Institute
Co-authored papers 1
Stephanos Ioannidis
H3 Biomedicine Inc.
Co-authored papers 1
Steven W Criscione
Oncology R&D
Co-authored papers 1
Joshua Armenia
Oncology R&D
Co-authored papers 1
Kathleen Burke
Oncology R&D
Co-authored papers 1
Release 1.2